Protego Biopharma Secures $100M to Advance Novel Approach to AL Amyloidosis Treatment
Protego Biopharma recently announced a $100 million Series B financing round, fueled by promising pre-clinical data and a strategy that tackles AL amyloidosis – a rare, life-threatening disease – at its root cause. This funding positions the company to move its lead candidate, PROT-001, into pivotal clinical trials, offering potential hope for patients wiht limited treatment options. But what makes Protego’s approach different, and why is this news significant?
Understanding AL amyloidosis & The Current Treatment Landscape
AL amyloidosis occurs when abnormal light chain proteins misfold and accumulate in organs, disrupting their function. This buildup,known as amyloid,can affect the heart,kidneys,nerves,and other vital tissues. Currently, treatments focus on reducing the production of these abnormal proteins, frequently enough through chemotherapy. However, these therapies don’t address the underlying protein instability, and existing damage remains.
“You can remove some of the aggregates, but you’re not removing the toxic light chain that’s still floating and available to continuously insult the cells,” explains Protego’s CEO, David warner. This highlights a critical unmet need: a therapy that stabilizes the proteins before they misfold and form damaging amyloid deposits.
Protego’s Innovative Protein Stabilization Strategy
Protego’s approach centers around stabilizing the misfolding proteins, preventing them from aggregating and causing harm. This “upstream” strategy, as Warner describes it, could lead to better clinical outcomes compared to treatments that only address established amyloid plaques.
This isn’t a new concept for the team behind Protego. Their work builds directly on the success of tafamidis (Vyndaqel and Vyndamax), a blockbuster drug marketed by Pfizer for transthyretin amyloidosis (ATTR). Like AL amyloidosis, ATTR involves misfolded proteins forming amyloid deposits.
* Tafamidis’ Success: Pfizer acquired FoldRx Pharmaceuticals, the original developer of tafamidis, in 2010. The drug has as become a highly successful treatment for ATTR cardiomyopathy.
* Protego’s Lineage: protego was co-founded in 2017 by Jeffery Kelly, the scientific founder of FoldRx, and includes many former FoldRx employees. This deep expertise in protein folding is a key strength.
Essentially,Protego is applying lessons learned from ATTR amyloidosis to tackle the challenges of AL amyloidosis. They’re leveraging a proven principle - protein stabilization – to address a different, but related, disease.
What’s Next for PROT-001?
Protego is currently conducting a Phase 1 study in Australia, evaluating the safety and pharmacokinetics of PROT-001 in healthy volunteers.Beyond safety, the study aims to:
* Confirm the drug is reaching its target.
* Measure how the drug is distributed throughout the body.
* Determine the drug’s half-life to inform optimal dosing (once or twice daily).
Data from this Phase 1 trial are anticipated in early 2025. If all goes well, Protego plans to initiate a Phase 2/3 clinical trial in late 2026. The company is utilizing its proprietary AmyLite assay to confirm target engagement.
A Strong Investor Base Backs Protego’s Vision
The $100 million Series B round included participation from both existing and new investors, including:
* Vida Ventures
* MPM BioImpact
* Lightspeed Venture Partners
* Scripps research
* Omega Funds
* Droia Ventures
* YK Bioventures
* Digitalis Ventures
This robust investment underscores the confidence in Protego’s approach and its potential to significantly impact the lives of patients with AL amyloidosis.
Why This Matters to You
If you or a loved one is affected by AL amyloidosis, Protego’s progress offers a glimmer of hope. Their focus on stabilizing proteins before damage occurs represents a perhaps transformative approach. While still early in development, PROT-001 could offer a much-needed new treatment option for this devastating disease.
Disclaimer: *I am
Worth a look